Biogen (BIIB)/Forward Pharma (FWP) on Watch Amid Oral Interference/IPR Hearings

November 30, 2016 1:22 PM EST

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Biogen (NASDAQ: BIIB) and Forward Pharma (NASDAQ: FWP) could be volatile as the USPTO interference and IPR oral hearing is today. The trial could potentially have a significant impact on Biogen's Tecfidera.

Shares of BIIB are down 1.8% currently and FWP is flat and hasn't traded.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment